Oral GLP-1 weight-loss pills Wegovy and Foundayo launch in Australia
仅事实

Oral GLP-1 weight-loss pills Wegovy and Foundayo launch in Australia

摘要

Novo Nordisk's Wegovy and Eli Lilly's Foundayo tablets are now available by prescription, prompting expectations of increased use while health experts warn of unknown long-term risks.

Australia's pharmacies will begin dispensing the first approved oral GLP-1 tablets for weight management and type 2 diabetes after the Therapeutic Goods Administration granted approval. Novo Nordisk said its Wegovy pill will be on shelves from Friday, and Eli Lilly announced that its Foundayo tablet will arrive "in the coming days" following Monday's approval.

Clinicians welcomed the new option, noting that daily tablets taken on an empty stomach are easier to store and use than injectable versions, which require refrigeration. The medications are priced between AU$250 and AU$395 per month, comparable to the cost of GLP-1 injections, and availability will vary by pharmacy.

"We’ve got about 14 million people overall in Australia living with either overweight or obesity … and a proportion of them may want and need treatment to manage their condition," said Dr Mark Mellor, chair of the RACGP Specific Interests Obesity Management Group.

Pharmacist Catherine Bronger reported a surge in patient inquiries about Wegovy stock and advised customers to call ahead to confirm availability.

Health experts cautioned that long-term safety data are limited and that the drugs may be prescribed to individuals with healthy weights. Professor Barbara Mintzes highlighted concerns about potential nutritional deficiencies, muscle loss in older adults, pancreatitis, and a possible increased risk of thyroid cancer, noting that clinical trials paired the medication with intensive diet and exercise programs—a context not always communicated to the public.

Mintzes also pointed to marketing tactics that avoid direct-to-consumer advertising by using disease-awareness campaigns, which she said can shift the perception of obesity toward a purely medical problem with a pharmaceutical solution, potentially sidelining holistic lifestyle approaches.

The Australian government continues to face pressure to list GLP-1 medicines on the Pharmaceutical Benefits Scheme, as the high out-of-pocket cost is seen as a barrier for many people living with obesity.

来源

The Age

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。